Beilstein J. Nanotechnol.2023,14, 240–261, doi:10.3762/bjnano.14.23
intracellular internalization, and bring advantages over conventional nanocarriers.
Keywords: co-delivery nanoparticles; combinatorial therapy; EGFR TKI resistance; non-smallcelllungcancer (NSCLC); overcoming and preventing resistance; Introduction
Among the malignant diseases, lung cancer takes the lead
recorded worldwide for both genders, representing 18% of all cancer deaths [4]. There are two main classes of lung cancer based on histological appearance, namely small-cell lung cancer (SCLC), which is highly aggressive, and non-smallcelllungcancer (NSCLC), which is more prevalent (85% of all diagnosed
impact on the discovery of novel therapies based on specific histological types and molecular signatures of cancer. Molecularly targeted therapies that have been developed for a subgroup of non-smallcelllungcancer (NSCLC) with endothelial growth factor receptor (EGFR) activating mutations firmly
PDF
Figure 1:
Examples of combinatorial therapy for (left) EGFR-dependent and (right) EGFR-independent TKI resist...